奔驰彩票app下载 對于流利說而言，精細化運營是2020年的核心任務，退出“燒錢”大戰后，流利說在策略、渠道差異化運營方面進行了一系列嘗試 招商銀行也同日在公告中表示，為防范業務風險，保護投資者權益，招行將對零售貴金屬交易業務進行以下安排：自11月28日起，暫停招行各渠道（包括柜面、手機銀行、網上銀行、招銀匯金App等）雙向紙黃金白銀、實盤紙黃金白銀、招財金業務（代理上海黃金交易所業務）的新客戶開立交易賬戶申請，已開戶客戶的正常交易不受影響
- LYMPHBRIDGE [link] is a multi-site blinded clinical study evaluating the use of BioBridge in the treatment of acquired breast cancer-related lymphedema being conducted in the United States. This study, which is funded by a $3M SBIR Phase IIB Bridge grant by the National Cancer Institute (NCI), will begin enrollment in September 2020 and is being led by University of Chicago Medicine and Stanford Medicine.
- A pilot clinical study is being conducted in Europe to evaluate using BioBridge as a preventative treatment for patients who are at high risk of developing lymphedema from required surgery to address advanced stage breast cancer. This multi-site, blinded study will begin enrollment in September 2020 and is based on strong preclinical studies that demonstrated BioBridge was effective in providing an infrastructure that supported lymphatic tissue repair before lymphedema would develop. This initial preventative clinical study is sponsored by the Terumo Corporation.
- Fibralign is working with Terumo Corporation to prepare a clinical study in Japan scheduled for 2021 to evaluate the treatment of acquired lymphedema using BioBridge as a surgical implant. This study, which is being funded and managed by Terumo, will be used to gather clinical data to support PMDA regulatory engagement to market BioBridge in Japan.